The microsite is supported by AbbVie.

As a global, research-driven biopharmaceutical company, AbbVie is committed to treating serious, mostly chronic diseases. Research and innovation are the foundation of the company’s operations. Therapeutic areas include rheumatology.

Highlights

Professional article
View Post

Digital tools as support for predict-to-treat?

In contrast to other therapeutic areas, it is still difficult to achieve remission in all patients in rheumatology. Two applications can increase the chance of clinical remission through joint decision-making between patients and the medical profession [1-4]. One is the treat-to-target (T2T ) strategy and the other is the predict-to-treat (P2T ) concept, in which digital tools can help predict outcomes or monitor disease progression [5]. On the eve of the SGR Annual Congress from August 31 – September 1, 2023, Prof. Dr. med. Gerd Burmester (Charité Universitätsmedizin, Berlin) and Prof. Dr. Dr. Thomas Hügle (Centre hospitalier universitaire vaudois, Lausanne) spoke about the two concepts in the familiar setting “Room-for-Rheum”. The highlights are summarized for you below…. This content can…
View Post

The treatment landscape for chronic inflammatory rheumatic diseases offers scope for individual treatment decisions

With the ongoing expansion of the therapeutic landscape, treatment management for chronic inflammatory rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) is also changing. The diseases are often associated with physical and psychological limitations and remission is the primary treatment goal in order to improve the patient’s quality of life.1-5 Individual treatment decisions play an important role here.6 At the annual congress of the Swiss Society of Rheumatology (SGR), treatments for RA, PsA and AS were discussed at an interactive symposium…. This content can only be access by registered users. Log In Register
View Post

RA patient with severe polyarthritis on JAK inhibitor in remission for more than one year

Rheumatoid arthritis (RA) is associated with a high level of suffering for those affected and, if left untreated, can lead to disability. Below, Ioannis Papadopoulos, MD, presents a case in which a 54-year-old food service worker with several years of severe RA achieved the therapeutic goal of ongoing freedom from symptoms with the help of a Janus kinase (JAK) inhibitor…. This content can only be access by registered users. Log In Register
View Post

Current data and expert opinions on the therapeutic goal of remission

The management of inflammatory rheumatic diseases has improved significantly in recent years with the development of targeted treatments [1]. But how realistic is achieving remission today? The following report provides a summary of current data and the assessments of various experts on the therapeutic goal of remission in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis…. This content can only be access by registered users. Log In Register
View Post

“With the JAK inhibitors, we can get much more out of them for our patients”

Oral Janus kinase inhibitors (JAKi) have been expanding the treatment landscape for inflammatory rheumatoid diseases for several years. In the following interview, Prof. Dr. med. Gerd Burmester explains what this means for the management of these diseases and what points there are to consider with regard to the effectiveness and safety of JAKi. … This content can only be access by registered users. Log In Register
View Post

What you always wanted to know about JAK inhibitors

Oral Janus kinase inhibitors (JAKi) are gaining ground in the treatment of inflammatory rheumatoid diseases and were therefore a hotly debated topic at this year’s annual congress of the Swiss Society of Rheumatology (SGR). Prof. Dr. med. Andrea Rubbert-Roth and Prof. Dr. med. Gerd Burmester provided information on current developments…. This content can only be access by registered users. Log In Register
View Post

“When those affected forget about the disease in their daily lives, it’s a particularly nice moment for us physicians.”

Every year on October 12 is World Rheumatism Day. This was launched in 1996 by the international federation of self-help associations of rheumatism sufferers, “Arthritis and Rheumatism International (ARI)”. When people talk about rheumatism, they are grouping together 200 to 400 individual diseases. One of these diseases is rheumatoid arthritis (RA), a so-called autoimmune disease that causes inflammation in the joints, leading to swelling and severe pain. RA is the most common chronic joint disease. On the occasion of this year’s World Rheumatism Day, Valérie Krafft, Managing Director of the Rheumatism League Switzerland, Dr. med. Heino Prillwitz, specialist in rheumatology from Weinfelden, and the affected person, My To-Siegrist, talk about RA…. This content can only be access by…
View Post

“You have to stop treating psoriasis as just a skin disease”.

In Switzerland, psoriasis affects about 1 to 3 percent of the population [1]. About one in three psoriasis patients also suffers from psoriatic arthritis (PsA), a chronic inflammatory systemic disease that can manifest itself in arthritis, enthesitis, and dactylitis, among other things [2, 3]. If left untreated, PsA can result in joint destruction and even disability [2]. In the following interview, dermatologist Prof. Thomas Kündig and rheumatologist Prof. Diego Kyburz discuss the interdisciplinary management of this complex disease and elaborate on two current therapeutic options [4, 5]…. This content can only be access by registered users. Log In Register
View Post

Additional therapeutic option available for psoriatic arthritis [1].

Psoriatic arthritis (PsA) affects about one in three patients with psoriasis and, if left untreated, can lead to severe physical limitations and a reduced quality of life [2,3]. With the newly obtained reimbursement of a biologic, adults with PsA can now benefit from a long-term effective treatment option with a stable safety profile and patient-friendly use [1,4,5]…. This content can only be access by registered users. Log In Register
View Post

Remission as the primary treatment goal

Patients with chronic inflammatory rheumatic diseases often suffer from pain, comorbidities, and physical and social limitations, resulting in immense impairment of quality of life [1, 2]. In order to improve the situation of those affected by RA, AS and PsA, the achievement of remission is the primary therapeutic goal [1, 3, 4]…. This content can only be access by registered users. Log In Register
istock-1300745916
View Post

“I love doing research in the field of rheumatology”

The AbbVie Rheumatology Fellowship has supported training of young researchers since 2004. Learn more about how it is helping last year’s awardee, Dr. med. Cosimo Bruni, University Hospital Zurich, to improve his skills as a researcher in rheumatology and find out how to apply for the AbbVie Rheumatology Fellowship 2022!… This content can only be access by registered users. Log In Register
View Post

“Anyone diagnosed with RA today wants to be completely symptom-free.”

With the development of conventional, biologic, and targeted disease-modifying antirheumatic drugs, the prognosis for rheumatoid arthritis has improved significantly since the 1990s. However, many patients still do not respond to available treatments [1,2]. In an interview, Prof. Andrea Rubbert-Roth, MD, explains the opportunities offered by new therapy options and what the focus is on for patients…. This content can only be access by registered users. Log In Register
View Post

“Rheumatic diseases still meet with a lot of misunderstanding from the public”

The Swiss Rheumatism League has been working for people with rheumatism since 1958. In an interview, Executive Director Valérie Krafft explains how the non-profit organization supports those affected, why the increasing amount of information available is both a curse and a blessing, and what needs exist with regard to disease management…. This content can only be access by registered users. Log In Register
View Post

Facing the challenges of psoriatic arthritis management

Despite remarkable progress in the treatment of patients with psoriatic arthritis (PsA), the management of this chronic disease still poses major challenges [1]. In the following interview, Prof. Pascal Richette, MD, from Paris, explains how new therapies can help achieve ambitious goals in terms of efficacy, tolerability and patient satisfaction…. This content can only be access by registered users. Log In Register
View Post

Lasting remission through targeted treatment

Despite great advances in the management of rheumatoid arthritis, many patients do not respond satisfactorily (or adequately) to available treatments [1]. Data from clinical trials of a targeted disease-modifying antirheumatic drug show that with additional effective therapeutic options, more and more RA patients can also achieve the goal of remission in the long term [2, 3]…. This content can only be access by registered users. Log In Register
View Post

Let’s talk about JAKs

The treatment of rheumatoid arthritis (RA) has made great progress over the past 20 years. This relates both to the range of drugs available and to developments in terms of rapid onset of action and response rates. Phase III clinical trials were published in 2019, particularly for JAK inhibitors, and the results were presented at the Rheumatism Update in Wiesbaden…. This content can only be access by registered users. Log In Register
View Post

New JAK inhibitor raises hopes

Treatment with disease-modifying antirheumatic drugs (DMARDs) plays an important role in modern therapeutic concepts for rheumatoid arthritis. If left untreated, joint destruction and loss of mobility are possible consequences of this autoimmune-mediated chronic inflammatory disease. A new member of the Janus kinase (JAK) inhibitor class has been shown to be effective and safe in clinical trials…. This content can only be access by registered users. Log In Register